Literature DB >> 17196931

Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice.

Shin-ichiro Nakagawa1, Takuya Umehara, Chiho Matsuda, Shusuke Kuge, Masayuki Sudoh, Michinori Kohara.   

Abstract

Persistent infection with hepatitis C virus (HCV) is a major cause of liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Here we report that inhibition of heat shock protein 90 (Hsp90) is highly effective in suppressing HCV genome replication. In HCV replicon cells, HCV replication was reduced by Hsp90 inhibitors and by knockdown of endogenous Hsp90 expression mediated by small-interfering RNA (siRNA). The suppression of HCV replication by an Hsp90 inhibitor was prevented by transfection with Hsp90 expression vector. We also tested the anti-HCV effect of Hsp90 inhibition in HCV-infected chimeric mice with humanized liver. Combined administration of an Hsp90 inhibitor and polyethylene glycol-conjugated interferon (PEG-IFN) was more effective in reducing HCV genome RNA levels in serum than was PEG-IFN monotherapy. These results suggest that inhibition of Hsp90 could provide a new therapeutic approach to HCV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196931     DOI: 10.1016/j.bbrc.2006.12.117

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  43 in total

1.  Inhibition of heat-shock protein 90 reduces Ebola virus replication.

Authors:  Darci R Smith; Sarah McCarthy; Andrew Chrovian; Gene Olinger; Andrea Stossel; Thomas W Geisbert; Lisa E Hensley; John H Connor
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

Review 2.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

3.  Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeutics.

Authors:  Michael R Defee; Zhiqiang Qin; Lu Dai; Jennifer S Isaacs; Chris H Parsons
Journal:  Am J Cancer Res       Date:  2011-06-05       Impact factor: 6.166

4.  Hepatitis C virus inhibitor synergism suggests multistep interactions between heat-shock protein 90 and hepatitis C virus replication.

Authors:  Naoko Kubota; Masataka Nomoto; Gi-Wook Hwang; Toshihiko Watanabe; Michinori Kohara; Takaji Wakita; Akira Naganuma; Shusuke Kuge
Journal:  World J Hepatol       Date:  2016-02-18

5.  Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice.

Authors:  Aditya Ambade; Donna Catalano; Arlene Lim; Pranoti Mandrekar
Journal:  Hepatology       Date:  2012-03-18       Impact factor: 17.425

6.  Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection.

Authors:  Naoki Mori; Kazunori Nakasone; Koh Tomimori; Chie Ishikawa
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

Review 7.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

8.  Two-dimensional blue native/SDS-PAGE analysis reveals heat shock protein chaperone machinery involved in hepatitis B virus production in HepG2.2.15 cells.

Authors:  Kun Liu; Lu Qian; Jinglan Wang; Wenrui Li; Xinyu Deng; Xilin Chen; Wei Sun; Handong Wei; Xiaohong Qian; Ying Jiang; Fuchu He
Journal:  Mol Cell Proteomics       Date:  2008-11-04       Impact factor: 5.911

9.  Proteomic analysis of purified coronavirus infectious bronchitis virus particles.

Authors:  Qingming Kong; Chunyi Xue; Xiangpeng Ren; Chengwen Zhang; Linlin Li; Dingming Shu; Yingzuo Bi; Yongchang Cao
Journal:  Proteome Sci       Date:  2010-06-09       Impact factor: 2.480

10.  Identification of cellular proteome modifications in response to West Nile virus infection.

Authors:  Boris Pastorino; Elodie Boucomont-Chapeaublanc; Christophe N Peyrefitte; Maya Belghazi; Thierry Fusaï; Christophe Rogier; Hugues J Tolou; Lionel Almeras
Journal:  Mol Cell Proteomics       Date:  2009-04-24       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.